Abstract
Diabetic retinopathy and glaucoma are major diseases that cause blindness in a high percentage of the population. However, the precise mechanisms involved in the onset and the progression of these diseases are still not completely known. Recent studies have shown that there appears to be an association between these two disease processes because the incidence of glaucoma is higher in diabetic patients than in non-diabetic patients. To reduce the number of patients with vision loss from these diseases, new therapeutic strategies must be established to prevent the development and the progression of these diseases. In this report, we focus on the biochemical links between diabetic retinopathy and glaucoma, viz., an overexpression of extracellular matrix and death of retinal ganglion cells. To establish new therapeutic strategies for both diseases, the biochemical links between diabetic retinopathy and glaucoma and an identification of the factors that are common to the pathogenesis of both diseases, must be determined. In addition, the potential use of gene therapies including antisense oligonucleotides and small interference RNAs should be considered for both diseases. We expect that with the advent of new therapies, a larger number of patients with diabetic retinopathy and/or glaucoma will be cured.
Keywords: Diabetic retinopathy, glaucoma, extracellular matrix, retinal ganglion cell death, antisense oligonucleotides, small interference RNA
Current Drug Therapy
Title: Common Therapeutic Strategies for Diabetic Retinopathy and Glaucoma
Volume: 2 Issue: 3
Author(s): Toshiyuki Oshitari and Sayon Roy
Affiliation:
Keywords: Diabetic retinopathy, glaucoma, extracellular matrix, retinal ganglion cell death, antisense oligonucleotides, small interference RNA
Abstract: Diabetic retinopathy and glaucoma are major diseases that cause blindness in a high percentage of the population. However, the precise mechanisms involved in the onset and the progression of these diseases are still not completely known. Recent studies have shown that there appears to be an association between these two disease processes because the incidence of glaucoma is higher in diabetic patients than in non-diabetic patients. To reduce the number of patients with vision loss from these diseases, new therapeutic strategies must be established to prevent the development and the progression of these diseases. In this report, we focus on the biochemical links between diabetic retinopathy and glaucoma, viz., an overexpression of extracellular matrix and death of retinal ganglion cells. To establish new therapeutic strategies for both diseases, the biochemical links between diabetic retinopathy and glaucoma and an identification of the factors that are common to the pathogenesis of both diseases, must be determined. In addition, the potential use of gene therapies including antisense oligonucleotides and small interference RNAs should be considered for both diseases. We expect that with the advent of new therapies, a larger number of patients with diabetic retinopathy and/or glaucoma will be cured.
Export Options
About this article
Cite this article as:
Oshitari Toshiyuki and Roy Sayon, Common Therapeutic Strategies for Diabetic Retinopathy and Glaucoma, Current Drug Therapy 2007; 2 (3) . https://dx.doi.org/10.2174/157488507781695685
DOI https://dx.doi.org/10.2174/157488507781695685 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotective Effects of Ellagitannins: A Brief Review
Current Drug Targets DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Transplantation Tolerance by Donor MHC Gene Transfer
Current Gene Therapy Modulation of Neutrophil Development and Homeostasis
Current Molecular Medicine Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids
Medicinal Chemistry Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine Cardioprotection with opioids - Trusted old friends -Clinical Science -
Current Pharmaceutical Design Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Are Chemically Reactive Metabolites Responsible for Adverse Reactions to Drugs?
Current Drug Metabolism Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis
Current Pharmaceutical Design Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?
Current Drug Therapy Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology